TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Verbal numeric pain score with hip flexion at 6hrs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Motor Examination Part III Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Information sharing among relatives
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Objective response rate (complete response/partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of pediatric patients with pathway alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients receiving cardiac output monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Leukocyte phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Opsonophagocytic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Whole blood response to pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Acceptance or Refusal of a Feeding Tube for Chronic Aspiration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptance or Refusal of Antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptance or Refusal of Breathing Machine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptance or Refusal of Tracheostomy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CHF Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of subjects tolerant to hypoallergenic formula
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of CXCL8 Cytokine in Cell Supernatant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Viable Cells Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Fluorescence Units of STAT1 Protein Phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal Pocket Depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C Reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of polyparasitism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Marginal gingival recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of vaccinated subjects without adverse events by Day 730
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of vaccinated subjects with adverse events by Day 730
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of vaccinated subjects with any severity of local reactions (Grades 1-4) by Day 730
Endpoint domain: Adverse events/effects
Primary endpoint: percentage change in volumetric measurement of the index lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with urinary tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Completion of the WORQ questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in regional cerebral oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Camostat Related AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of AEs by Severity Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Lack of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Histopathologically confirmed high grade cervical lesions and cervical cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bacteremia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Life events preceding PR symptoms
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in mean double support percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Functional ambulation profile (FAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-TPO antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Anti-thyroglobulin antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: fatty acid kinetics in total plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fatty acid kinetics in cholesterol ester
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fatty acid kinetics in triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fatty acid kinetics in phospholipid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fatty acid kinetics in monoglyceride subfraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fatty acid kinetics in diglyceride subfraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insomnia Severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Postprandial GLP-1 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of Patients Adequately Sedated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of clinical events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in UCLA-PTSD-RI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maneuverability score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infection-induced organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of immune-related adverse events (irAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivities and Specificities for diagnosis of sleep apnoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Proportion of time with SpO2 within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Numeric rating scale (NRS) for lower back related pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry disability index (ODI) version 2.1
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of participating patients receiving specialist care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Anogenital distance measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in smoking hygiene practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta left ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Geographic Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Daily Total Nasal Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolomic profile analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Iron Absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change in Average Severity for Abdominal/Pelvic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: pancreatic tumor response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of Medication-taking (% Taking Adherence)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pattern of Medication-taking (% Scheduling Adherence)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduced leaflet motion and/or valve thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety profile of Sorafenib
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of Sorafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regression of carotid atherosclerotic plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients using CPAP for more than 3 hours per night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of everolimus
Endpoint domain: Adverse events/effects
Primary endpoint: Stage of hepatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change of stroke volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Muscle fiber myonuclear and stem cell content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cognition measured by Oral Symbol Digital Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Panel of tumor proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: episodes of poor asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sebum secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes of Total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major Perioperative Morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in IMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in CFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Success Rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: molecular markers in discarded tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilisation rates of molecular profiling information
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: immediate unaided and aided visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymph rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lymph Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Capillary filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Capillary filtration coefficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Isovolumetric pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Troponin I or T elevation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seroconversion rate for HI antibody after final injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection rate for HI antibody after final injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Verbal memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: neuromuscular neutral zones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent achieving HAI seroconversion against A/H7N9 antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects achieving a serum HAI antibody titer of 1:40 or greater against the A/H7N9 antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of hypothyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median Time to PSA Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in hyperphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) for PEG-IFN alfa-2a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC) for PEG-IFN alfa-2a From Time Zero to 816 hours (AUC0-816h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endothelial function (reactive hyperemic index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in daily symptom levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Baseline Dolorimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of in hospital cardiac arrest
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent bleeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in PHQ-9 Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BIS changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of individuals with viral failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: oral hygiene related self-efficacy (OHSE) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in BPSD measure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prolactin receptors expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Ankylosing Spondylitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of orthostatic intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Adaptive Speech in Noise Test Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation marker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of antibodies against Measles, Mumps, Rubella and Varicella
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative Hospital Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean Change in Diary Brief Pain Inventory Score of Average Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of respiratory symptoms in COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Assessment of respiratory symptoms in Dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Assessment of respiratory symptoms in Asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximal diameter estimate by imaging modality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal diameter based on histopathology gold standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Events
Endpoint domain: Adverse events/effects
Primary endpoint: Total pathologic complete response (tpCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: True Positives for Pulmonary Arterial Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bleeding Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriological Culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Readmission rate within 30 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Serum Inaba vibriocidal antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic yield of tumor perfusion measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Who Completed Early Intervention Intake and Evaluation Visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Estimated Glomerular Filtration Rate (eGFR) at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Pharyngeal Critical Collapsing Pressure (Pcrit)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Treatment success with inhibiting CA IX enzyme levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-peptide production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number and Severity of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: FDG Therapeutic Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FLT Therapeutic Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RECIST 1.1 Therapeutic Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the non-invasive device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of those lost to follow-up who are no longer engaged in HIV care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ABT-614 levels in cerebral spinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABT-614 levels in blood (plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of Cefazolin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) from zero to infinity [AUC(0-inf)] of riociguat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of riociguat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excess time to first ACHD clinic appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage change in Eczema Area Severity Index (EASI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in rate of canine retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IL-1β level in the Gingival Crevicular Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with postpartum depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cardiac output maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of respiratory infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Seroconversion rate of EV71 neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in microvascular blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in microvascular endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in macrovascular endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of single nucleotide polymorphism (SNP) genotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Age of onset of prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Body alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Rate of Morphologic Complete Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cytogenetic Complete Remission (CRc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Morphologic Complete Remission With Incomplete Blood Count Recovery (CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes